Rita Jain
Direktor/Vorstandsmitglied bei CELLDEX THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Aktive Positionen von Rita Jain
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 16.02.2023 | - |
| Independent Dir/Board Member | - | - | |
| ANAPTYSBIO, INC. | Direktor/Vorstandsmitglied | 06.04.2023 | - |
| Independent Dir/Board Member | 06.04.2023 | - | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Direktor/Vorstandsmitglied | 01.07.2020 | - |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Direktor/Vorstandsmitglied | 01.01.2020 | - |
Karriereverlauf von Rita Jain
Ehemalige bekannte Positionen von Rita Jain
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PROVENTION BIO, INC. | Direktor/Vorstandsmitglied | 03.01.2023 | 27.04.2023 |
| CHEMOCENTRYX, INC. | Direktor/Vorstandsmitglied | 27.03.2019 | 20.10.2022 |
| Technik-/Wissenschafts-/F&E-Leiter | 11.10.2021 | 20.10.2022 | |
| Independent Dir/Board Member | 27.03.2019 | 11.10.2021 | |
| IMMUNOVANT, INC. | Technik-/Wissenschafts-/F&E-Leiter | 12.01.2021 | 01.06.2021 |
| AKEBIA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 25.05.2017 | 17.06.2019 |
| ABBVIE INC. | Corporate Officer/Principal | 01.01.2003 | 01.01.2012 |
| ░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░ ░░░░ ░░░░░░░░░░ ░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Ausbildung von Rita Jain
| Long Island University | Undergraduate Degree |
| Stony Brook University School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 13 |
| Niederlande | 3 |
Operativ
| Director/Board Member | 6 |
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 3 |
Sektoral
| Health Technology | 10 |
| Consumer Services | 4 |
| Health Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| ABBOTT LABORATORIES | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| ANAPTYSBIO, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
North Shore University Hospital
 North Shore University Hospital Hospital/Nursing ManagementHealth Services North Shore University Hospital Manhasset provided health care services. The company was headquartered in Manhasset, NY. | Health Services |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Health Technology |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
